403
Views
16
CrossRef citations to date
0
Altmetric
Reviews

Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Wolfgang H. Jost. (2023) A novel treatment option for intrajejunal levodopa administration. Expert Review of Neurotherapeutics 23:1, pages 9-13.
Read now
Meir Kestenbaum & Stanley Fahn. (2015) Safety of IPX066, an extended release carbidopa–levodopa formulation, for the treatment of Parkinson’s disease. Expert Opinion on Drug Safety 14:5, pages 761-767.
Read now

Articles from other publishers (14)

Emir Berberovic & Wolfgang H. Jost. (2023) Therapieansätze für das fortgeschrittene idiopathische Parkinson-Syndrom. DNP – Die Neurologie & Psychiatrie 24:6, pages 62-69.
Crossref
K. E. Grund, A. Zipfel, B. Duckworth-Mothes & W. H. Jost. (2023) Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome. Journal of Neural Transmission 130:11, pages 1383-1394.
Crossref
Dag Nyholm & Wolfgang H. Jost. (2022) Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance. Therapeutic Advances in Neurological Disorders 15, pages 175628642211080.
Crossref
Wolfgang H. Jost. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 3025 3050 .
Wolfgang H. Jost. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 2871 2889 .
Wolfgang H. Jost. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 26 .
Anuradha Sharma, Shikha Kalotra, Payal Bajaj, Harpal Singh & Gurcharan Kaur. (2019) Butanol Extract of Tinospora cordifolia Ameliorates Cognitive Deficits Associated with Glutamate-Induced Excitotoxicity: A Mechanistic Study Using Hippocampal Neurons. NeuroMolecular Medicine 22:1, pages 81-99.
Crossref
Luminita C. Popa, Daniel-Corneliu Leucuta, Nicoleta Tohanean, Stefan-Lucian Popa & Lacramioara Perju-Dumbrava. (2020) Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease. Medicine 99:46, pages e23249.
Crossref
Wolfgang H. Jost. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 19 .
Maria Gabriella Vita, Francesco Bove, Paolo Mariotti, Maria Elena Riccioni, Vincenzo Leuzzi & Anna Rita Bentivoglio. (2017) Levodopa-Carbidopa Intestinal Gel in a Pediatric Parkinsonism-plus Syndrome. Movement Disorders Clinical Practice 4:5, pages 791-792.
Crossref
Carsten Buhmann, R. Hilker, P. Lingor, C. Schrader, J. Schwarz, M. Wolz & H. Reichmann. (2017) Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. Journal of Neural Transmission 124:8, pages 1005-1013.
Crossref
W. H. Jost. (2017) Medikamentöse Therapie der motorischen Symptome beim Morbus ParkinsonPharmacological treatment of motor symptoms in Parkinson’s diseases. Der Nervenarzt 88:4, pages 373-382.
Crossref
Daniela CalandrellaLuigi M. RomitoAntonio E. EliaFrancesca Del SorboCaterina F. BagellaMassimo FalsittaAlberto Albanese. (2015) Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology 84:16, pages 1669-1672.
Crossref
Etheresia Pretorius, Albe C Swanepoel, Antoinette V Buys, Natasha Vermeulen, Wiebren Duim & Douglas B Kell. (2014) Eryptosis as a marker of Parkinson's disease. Aging 6:10, pages 788-819.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.